**A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study**

Professor Richard E. Clark, MD1, Fotios Polydoros, MSc2, Professor Jane F. Apperley, MD3, Dragana Milojkovic PhD3, Christopher Pocock, PhD4, Graeme Smith, MD5, Jenny L Byrne, PhD6, Hugues de Lavallade, MD7, Professor Stephen G O’Brien, PhD8, Tony Coffey2, Professor Letizia Foroni, PhD3 and Professor Mhairi Copland, PhD9

1 Institute of Translational Medicine, University of Liverpool, Liverpool, UK

2 CR-UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, UK

3 Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK

4 East Kent Hospitals, Canterbury, UK

5 Dept. of Haematology, Level 3, Bexley Wing, Leeds, UK

6 University of Nottingham, Nottingham, UK

7 Department of Haematological Medicine, Kings College Hospital, London, UK

8 Northern Institute for Cancer Research, Newcastle University, Newcastle, UK

9 Paul O'Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

**Financial support:** Bloodwise (grant number 13020) supported the trial and Newcastle University Clinical Trials Unit assisted with arrangements for trial funding.

**Corresponding Author:** Prof. Richard E. Clark,

Department of Haematology,

Royal Liverpool University Hospital,

Prescot Street,

Liverpool L7 8XP

United Kingdom

Email: [clarkre@liverpool.ac.uk](mailto:clarkre@liverpool.ac.uk).

Telephone: +44 (0)151-706-4297 or -4344

FAX: +44 (0)151-706-5810

**Running title:** DESTINY: TKI de-escalation in well controlled CML (50 characters)

Presented in part at the American Society of Hematology Annual Meeting, December 5th 2016, San Diego, CA, USA.

**Key words:** chronic myeloid leukaemia, tyrosine kinase inhibitors, stopping treatment, imatinib, nilotinib, dasatinib

**Word counts, etc:** abstract 279, text 2842 (including acknowledgements and statements on author contributions but not declaration of conflict of interests or the appendix listing the sites and their investigators).

4 tables (plus 1 supplementary table on-line only), 3 figures (including the compulsory CONSORT diagram), 19 references.

ABSTRACT

BACKGROUND: Discontinuation of tyrosine kinase inhibitor (TKI) therapy is feasible for some patients with chronic myeloid leukaemia (CML) with deep molecular responses, defined as stable MR4 (*BCR-ABL1/ABL1* ratio <0.01%). However, patients in stable major molecular response (MMR; MR3; *BCR-ABL1/ABL1* ratio consistently < 0.1%) but not MR4 have not hitherto been studied. In addition, the effect of treatment de-escalation rather than outright stopping has not been investigated so far.

PATIENTS and METHODS: This study recruited 174 British adult CML patients in first chronic phase who had received TKI for ≥3 years and were either in stable MR4 (the ‘MR4 cohort’ n=125) or in stable MMR but not MR4 (the ‘MMR cohort’; n=49) for ≥12 months. Participants received half their standard TKI dose for 12 months. Molecular recurrence was defined as loss of MMR (>0.1%) on two consecutive samples. The study endpoint is the proportion of patients who lose their MMR on de-escalation and regain MMR on TKI resumption. The trial was registered at <https://clinicaltrials.gov/> as NCT 01804985.

FINDINGS: During the 12 months of half-dose therapy, 12 patients had molecular recurrence, all of whom regained MMR within 4 months of full dose TKI resumption. Recurrence was lower in the MR4 cohort (3 of 121 evaluable patients; 2.5%, 90% CI: 0.2-4.8%) than in the MMR cohort (9 of 48 evaluable patients; 18.8%, 90% CI: 9.5-28%) (p = 0.0007), but was unrelated to prior TKI or TKI therapy duration. Many adverse events improved during the first 3 months of de-escalation, though not thereafter. Overall, de-escalation saved 46.7% from an expected TKI budget (without de-escalation) of £4,156,969.

INTERPRETATION: TKI de-escalation is safe for the vast majority of patients with excellent responses to TKI therapy, and is associated with improvement in symptoms and significant financial savings. The data imply that lower TKI doses may maintain responses in these patients.

FUNDING: Newcastle University and Bloodwise

INTRODUCTION

The advent of daily tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) has transformed the outlook for CML to a disease where the majority of patients can expect a normal life span.1 However, TKI therapy is not without adverse effects2 and is expensive3. This has led to CML specialists and patients asking whether after a few years of TKI therapy, the disease may be sufficiently suppressed to permit treatment discontinuation. Several studies have established that some patients with enduring deep molecular responses to TKI therapy can discontinue treatment (reviewed in4,5). Early studies were confined to patients with undetectable *BCR-ABL1* transcripts by standard reverse transcriptase polymerase chain reaction (RT-PCR), and defined molecular recurrence as the reappearance of *BCR-ABL1* transcript positivity6,7. More recent studies have specified recurrence as the loss of major molecular response (MMR, defined as *BCR-ABL1/ABL1* transcript ratio of >0.1%, also called MR3 [molecular response of 3 logs below an arbitrary standard baseline]). Using this definition of recurrence, at 24 months after TKI cessation the A-STIM and KIDS studies reported that 58-64% of patients are recurrence-free8, 9 and the large EUROSKI study of 868 patients similarly recently reported a rate of 52% at the same time point10.

However, these studies were confined to patients in stable MR4 at entry, i.e. whose *BCR-ABL1/ABL1* ratio is consistently below 0.01% (molecular response 4 logs below the standard arbitrary baseline). Although there are anecdotal reports of successful treatment cessation for a few months in patients in stable MMR but not MR4, e.g. during pregnancy11, such patients have not hitherto been formally studied in a stopping trial. In addition, TKI dose reduction in patients with good responses to TKI therapy but also troublesome adverse events can ameliorate these yet maintain deep molecular response2. We therefore questioned whether some patients who might experience molecular recurrence on stopping TKI might nevertheless have been able to safely decrease TKI treatment without an increase in tumour burden.

The present De-Escalation and Stopping Therapy with Imatinib, Nilotinib or sprYcel (DESTINY) study was designed to examine the effects of treatment de-escalation as a prelude to complete cessation, in patients not only with deep molecular responses of MR4 or greater, but also to include patients with MMR but not MR4. The cessation phase is ongoing; here we report that de-escalation is safe for the vast majority of patients and that it is associated with a decrease in the severity of adverse events and significant savings in TKI costs.

**PATIENTS and METHODS**

Entry/exclusion criteria

Trial entry was restricted to *BCR-ABL1* transcript positive patients with either an e13a2, e14a2 or e19a2 fusion transcript, aged 18 or over in first chronic phase of CML, who had either received the same TKI (imatinib, dasatinib or nilotinib) since diagnosis or had switched only once for intolerance to the initial drug. Patients who showed resistance to prior TKIs and switched to another TKI were excluded. Prior interferon treatment was not an exclusion criterion as long as it had finished at least 12 months before entry; Philadelphia chromosome positivity was not mandatory. Participants must have received TKI for at least 3 years, and all PCR tests (minimum of 3) in the 12 months before trial entry must have been ≤0.1% (i.e. MMR), each with ≥ 10,000 *ABL1* control transcripts. Patients who had previously received more than 400mg daily of imatinib or 100mg daily of dasatinib or 400mg twice daily of nilotinib were ineligible unless their high dose arose from participation in an earlier clinical trial in which higher doses were being compared with standard doses. Recipients of bosutinib or ponatinib at any point were ineligible. All entrants provided informed consent, and the trial was carried out in line with the Declaration of Helsinki, sponsored jointly by the University of Liverpool and Royal Liverpool & Broadgreen University Hospitals Trust, and they and the funding sources had no role in study design, or collection, analysis, or interpretation of the data or in the writing of this manuscript. Ethical approval was granted by the North West - Liverpool East Committee of the UK National Research Ethics Service. The trial was registered at <https://clinicaltrials.gov/> as NCT 01804985.

Trial design

Participants decreased their entry TKI to half the standard dose for 12 months, as follows: imatinib 200mg daily, dasatinib 50mg daily or nilotinib 200mg twice daily. Central monitoring was carried out monthly in a central laboratory at Imperial Molecular Pathology at Hammersmith Hospital, London, and all *BCR-ABL1* ratios were expressed according to International Scale. Any result > 0.1% prompted an urgent ‘alert’ to the site to request a further confirmatory sample, typically carried out within 2 weeks of the alerting sample. Molecular recurrence was defined as loss of MR3 (>0.1%) on these two consecutive samples and timed as the date of the first of these samples. In the event of recurrence, all patients were required to resume the standard dose of their entry TKI. Molecular monitoring continued monthly until MMR was reached again. The study endpoint is the proportion of patients who lose their MMR on de-escalation and regain MMR on TKI resumption.

Formal adverse event reporting was not attempted, though the presence and severity of TKI related symptoms were recorded at each monthly visit, both by verbal reporting and by the formal quality of life instruments EQ-5D12 and FACT-BRM13. In addition each patient was asked to complete a diary of symptoms arising between scheduled visits.

Sample size and statistical analysis

The trial was originally structured as 2 parallel cohorts, one comprising patients who were in MR4 for all assessments in the 12 months prior to entry, and the other for patients who were partially or wholly in MMR but not stable MR4 during this time. Since the latter cohort could be regarded as more experimental, this arrangement provided a mechanism for the independent Data Monitoring Committee to close that arm if its recurrence rate was unacceptably high, without prejudicing the MR4 cohort. The minimum required sample size (168) was calculated on the basis of the maximum width of the 90% confidence interval for a wide range of values of the proportion of relapsing patients; we required the maximum width for the smallest group to be smaller than 0.28.

Authors REC (corresponding author), FP and TC had full access to all of the data, and LF had access to the molecular data. Authors REC and FP had the final responsibility to submit for publication. All statistical analyses were performed on an intention to treat basis using the R Programming Language for Statistical Analyses, version 3.3.1. No adjustment for multiple testing or missing data was incorporated. The proportions of patients relapsing were estimated together with 90% confidence intervals. Survival distribution curves were estimated by the method of Kaplan and Meier. Five patients (3 imatinib, 1 each for nilotinib and dasatinib) were already on the half-dose at trial entry because of toxicity at standard/intermediate doses (their entry was not excluded in the protocol). These patients all continued on half-dose treatment and are included in all the analyses.

In the calculation of TKI drug costs, the UK National Health Service list price for each TKI dose was used, without any local discounts and without Value Added Tax (20% currently in the UK).

**RESULTS**

Between 16th December 2013 and 10th April 2015, 174 patients (male 98; female 76) were recruited after giving informed consent from 20 UK centres. Their flow through the trial is summarised in the CONSORT diagram in Figure 1. Of these, 125 fulfilled the definition for the MR4 cohort and 49 fell into the definition of ‘MMR but not MR4’ (hereafter referred to as ‘the MMR cohort’) as defined above. At entry, 148 patients were receiving imatinib, 16 nilotinib and 10 dasatinib. Details for the study population are given in Table 1. The median duration of TKI therapy was 7.7 and 6.5 years for the MMR and MR4 cohorts respectively though this was not significantly different; otherwise the MMR and MR4 cohorts were broadly comparable.

Effect of de-escalation on molecular recurrence

During the 12 months of half-dose therapy, 12 patients had molecular recurrence (loss of MMR), all of whom were receiving imatinib. Molecular recurrence was significantly lower in the MR4 cohort (3 of 121 evaluable patients; 2.5%, 90% CI: 0.2-4.8%) than in the MMR cohort (9 of 48 evaluable patients; 18.8%, 90% CI: 9.5-28%) (p = 0.0007). The median time to relapse was shorter in the MMR cohort than in the MR4 cohort (4.4 months vs. 8.7 months), as shown in Figure 2 panel A. As shown in Table 2, the probability of molecular recurrence on de-escalation was not related to age, gender, weight, performance status, *BCR-ABL1* transcript type, or the duration of TKI therapy (median 6.9 years overall). In this regard, no recurrences were observed in the quartile with the shortest prior TKI treatment (< 4.8 years), compared with 5/43 in the 2nd quartile (4.8-6.9 years), 4/43 in the 3rd quartile (6.9-10.2 years) and 3/44 in the 4th quartile (10.2-14.1 years). Too few data were available from diagnosis on the components (especially spleen size) of the Sokal, EURO/Hasford or more recent scoring systems to investigate whether these might predict molecular recurrence. Too few patients were receiving dasatinib or nilotinib to allow comparison of recurrence rates between imatinib and second generation TKI recipients. In addition, the probability of molecular recurrence was not related to simple blood count parameters (data not shown). Five patients (1 MMR and 4 MR4) did not complete 12 months of de-escalation for various reasons (poor protocol adherence (2 patients), relocation, pregnancy and intercurrent illness).

Table 4 shows that 22 patients entered the trial on lower than usual TKI doses. Two recurrences occurred among the 18 patients taking less than imatinib 400mg daily (11.1%), which is comparable to the 10 recurrences among 130 patients (7.7%) entering on 400mg daily. We cannot comment on the effect of lower entrance doses for dasatinib (2 cases) or nilotinib (2 cases) as no 2G TKI recipient had molecular recurrence.

No progression to advanced phase or loss of cytogenetic response was seen. No tyrosine kinase domain mutation was detected at the time of molecular relapse in any of 7 patients analysed to date by next generation sequencing. As shown in Figure 2 panel B, all 12 patients with molecular recurrence regained MMR within 4 months of resumption of full dose TKI (median time to recovery = 77 days). As shown in the CONSORT diagram of Figure 1, 36 (73%) patients in the MMR cohort and 117 (94%) in the MR4 cohort have proceeded to the currently ongoing stopping phase of the trial.

Effect of de-escalation on adverse events

Many patients described symptoms present at trial entry, either in verbal reporting at scheduled visits or in their diaries. In the first 3 months of de-escalation, many of these improved as shown in Figure 3. However, little further improvement was seen in the subsequent ~9 months. Details of symptoms that were not present at trial entry that arose during de-escalation are given in the Supplementary Table. Fifty-three new musculoskeletal symptoms were reported by 36 patients (21%), of which 43 were assessed as grade 1 (not interfering with the patient's usual function), and 10 as grade 2 (enough discomfort to interfere with usual activity). The episodes were described as cramps, arthritis or musculoskeletal pain. No grade 3 or 4 episodes were recorded. A similar pattern, albeit at lower frequency, was also observed for other common TKI adverse events, summarised in the Supplementary Table. Interestingly, all 12 recurrences occurred in the 138 patients that did not report any musculoskeletal withdrawal symptoms (i.e. recurrence rate of 8.7%).

During the course of the trial, 15 serious adverse events were reported, summarised in Table 3. All were assessed by sites as unrelated to the TKI or the underlying CML. They included one fatality due to worsening pre-existing peripheral arterial occlusive disease in a patient who had received only imatinib.

Formal quality of life assessments by EQ-5D and FACT-BRM were of marginal use as the mean scores for each instrument were similar to that of a healthy control population at trial entry and did not appreciably change during de-escalation (data not shown).

Financial effect of de-escalation

Table 4 gives details of the savings in drug costs during the 12 months of de-escalation. Figures are in UK pounds sterling throughout. In the UK, although the cost of imatinib is directly proportional to the dose used, this is not the case for nilotinib (400mg twice daily and 300mg twice daily cost the same) or dasatinib (100mg daily and 80mg daily cost the same). Among the 12 patients undergoing molecular recurrence, the timing of relapse and of the subsequent resumption of standard TKI dose was variable, resulting in saved TKI costs varying from £3,038 to £12,311 per relapsing patient. Overall, 46.7% (£1,943,364) was saved from an expected TKI budget (without de-escalation) of £4,156,969. If considering the MR4 cohort alone, the saving was 47.7% (£1,429,330 from an expected budget of £2,993,854). Similarly, in the MMR cohort alone, the saving was 44.2% (£514,034 from an expected budget of £1,163,115).

**DISCUSSION**

Although several studies of TKI cessation have been reported, almost nothing is known about the feasibility of treatment de-escalation in patients with stable molecular responses. A single-arm study commenced in 2008 of 76 patients aged 65 years or older who had received imatinib for at least 2 years and in stable complete cytogenetic response (for at least 1 year) examined intermittent imatinib (1 month on alternating with 1 month off). Almost all entrants were in fact also in MMR. With a minimum follow-up of 4 years, 27 patients (35%) lost MMR (and 13 (17%) lost cytogenetic remission)14, though all patients with adequate follow up regained MMR within 7 months. In the present study, we demonstrate 3 principal findings. Firstly, with a molecular recurrence rate of 2.5% after 12 months, de-escalation is clearly safe for patients in stable MR4 or deeper remission. Similarly, since 81% of patients in stable MR3 though not MR4 remain recurrence-free at 12 months, it is also clinically reasonable to offer de-escalation to such patients. It has been suggested that the absence of stable MR4 should be a ‘red light’ warning against treatment cessation4. The present report is confined to treatment de-escalation so does not allow comment on this, but does suggest that as long as the patient is in stable MMR, de-escalation may be a reasonable option. Also, our findings cannot be generalised to patients with excellent responses to a TKI given as second line after initial resistance, since these patients were excluded here. It is of interest that all 12 patients experiencing molecular recurrence were among the 148 receiving imatinib, while no recurrences were seen in the recipients of second generation TKI; this difference was not statistically significant. Since all relapsing patients promptly returned to MMR or better within 4 months of resumption of full TKI dose, it is plausible that de-escalation should become the standard of care for such patients.

Secondly, this practice-changing view is reinforced by the demonstration of general improvement of adverse events in both the MMR and MR4 cohorts, with only mild (none > grade 2 severity) and transient evidence of the musculoskeletal symptoms that have recently been described on complete TKI withdrawal9,15. Although these and other symptoms generally improved during de-escalation as shown in Figure 3, this trend was not of sufficient strength to be detectable by the quality of life assessment tools used here, emphasising their inappropriateness for well controlled CML patients in the TKI era16,17. Quality of life data using a symptom assessment tool more dedicated to TKI-treated CML patients18,19 would be of interest in future studies of TKI de-escalation/discontinuation. Although the trial protocol required patients with molecular recurrence to resume their TKI at full dose until MMR was re-attained, it would be interesting to formally study whether it is possible to subsequently resume reduced-dose treatment without molecular recurrence.

Thirdly, de-escalation in the MR4 cohort alone, the MMR cohort alone or the combined population is associated with a saving of almost half their expected TKI costs. The exact magnitude of these savings is dependent on local base prices, including any taxes, and for imatinib these are currently falling as generic alternatives are introduced. Although we have used individual patient TKI consumption data, it does not take account of the increased PCR monitoring and associated clinical visits that are advisable in patients undergoing de-escalation (or complete cessation). These appear very unlikely to significantly impact on the impressive savings on TKI costs, though require further study in trials incorporating detailed pharmaco-economic evaluation of TKI de-escalation/cessation.

In summary, in CML patients with stable MR3 or better, decreasing TKI treatment to half the standard dose appears safe, and is associated with improvement in TKI related side effects, implying that many patients with stable responses may be able to maintain their responses on lower TKI doses. De-escalation is also associated with substantial financial savings. Studies of more ambitious de-escalation are warranted.

**ACKNOWLEDGEMENTS**

The authors are indebted to the Liverpool Cancer Trials Unit, who have co-ordinated the trial, and to the enthusiasm of the clinical teams and their patients at all 20 participating sites. The authors also gratefully acknowledge the support of Newcastle University Clinical Trials Unit. JFA and LF acknowledge support of the NIHR Imperial College Biomedical Research Centre. Finally, the support of Bloodwise (grant number 13020) is gratefully acknowledged.

**AUTHOR CONTRIBUTIONS**

REC is the Chief Investigator. He has contributed to the study design, data collection and data interpretation, and wrote the manuscript.

FP is the study's statistician and has contributed generally but focussed on data analysis and has co-written the manuscript.

TC is the study co-ordinator, in charge of site set up, sponsor liaison and administrative aspects of study administration, and contributing to central data collection.

LF has been responsible for all the PCR laboratory studies.

The study management group comprised REC, MC, SO'B and LF, together with TC and FP.

All authors contributed to study design and commented on and approved the manuscript.

REC, JFA, DM, CP, GS, JLB, HdL, SO'B, and MC were all Principal Investigators at their various sites and recruited patients.

**DECLARATION of INTERESTS**

REC reports other grants from Bloodwise during the conduct of the study; grants and personal fees from Novartis, Bristol Myers Squibb and Pfizer, and personal fees from Ariad/Incyte, outside the submitted work. JFA reports grants and personal fees from Ariad/Incyte and Pfizer, and personal fees from Bristol Myers Squibb and Novartis, outside the submitted work. DM reports personal fees from Novartis, Bristol Myers Squibb, Pfizer and Ariad/Incyte, outside the submitted work. GS reports personal fees from Pfizer, Bristol Myers Squibb and Novartis, outside the submitted work. JLB reports personal fees from Novartis pharmaceuticals, Pfizer, Ariad / Incyte and Bristol Myers Squibb, outside the submitted work. HdL reports grants and personal fees from Ariad/Incyte, grants from Bristol Myers Squibb and personal fees from Novartis and Pfizer, outside the submitted work. SGO'B reports grants from Ariad during the conduct of the study; grants and personal fees from Bristol Myers Squibb and personal fees from Pfizer, outside the submitted work. MC reports grants from Bloodwise during the conduct of the study; personal fees from Ariad/Incyte and Pfizer, personal fees and non-financial support from Novartis Pharma and Bristol-Myers Squibb, outside the submitted work. FP, CP, TC and LF declare no conflict of interests.

**TABLE and FIGURE LEGENDS**

Table 1. Patient characteristics at trial entry. IQR = interquartile range. *BCR-ABL1* data are the centralised results at trial entry.

Table 2. Effect of various parameters on molecular recurrence. Data are frequency (proportion) for categorical variables, and median (IQR) for continuous variables. Statistical tests are Fisher’s exact test for categorical variables and the Mann-Whitney U-test for continuous variables.

Table 3. Serious adverse events during de-escalation. SAE = serious adverse event. Data are the number of SAEs (number of patients). Grading is according to the National Cancer Institute Common Toxicity criteria. \* denotes the single fatality.

Table 4. Financial implications of de-escalation. All costs are in pounds sterling using the UK National Health Service list price, exclusive of Value Added Tax. Costs for imatinib are for commercial Glivec®. UPN = unique patient number.

Figure 1. CONSORT diagram of patient disposition during de-escalation.

Figure 2. Molecular recurrence-free survival (panel A) and time to re-attaining MMR (panel B), for the MMR and the MR4 cohorts. Numbers at risk are as stated. The hazard ratio for the difference in recurrence free survival between the two groups is 0.12 (90% Confidence Interval = 0.04 – 0.37).

Figure 3. Evolution of patient-reported symptoms by month, for the MMR (left panel) and MR4 (right panel) cohorts.

Table 1. Patient characteristics at trial entry.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **MMR**  **N = 49** | **MR4**  **N = 125** | **Overall**  **N = 174** |
| ***Demographic Characteristics*** | | | |
| Age  median (IQR) | 57  (45, 66) | 61  (51, 68) | 59  (50, 68) |
| Gender  Male [n (%)] | 25 (51%) | 73 (58%) | 98 (56%) |
| ***Physical findings*** | | | |
| Weight  median (IQR)  *Missing* | 79  (70, 89)  *1* | 81  (72, 94)  *-* | 81  (72, 92)  *1* |
| ECOG performance status [n, (%)]  0 - Fully Active  1 - Work Able  2 - Not Work Able  3 - Limited Self Care  4 - Completely Disabled | 42 (86%)  7 (14%)  -  -  - | 113 (90%)  10 (8%)  1 (1%)  1 (1%)  - | 155 (89%)  17 (9%)  1 (1%)  1 (1%)  - |
| ***Clinical characteristics*** | | | |
| *BCR-ABL1/ABL1* transcript ratio (%)  median (IQR, range) | 0.0047  (0.002, 0.009) | 0.001  (0.0003, 0.002) | 0.001  (0.0006, 0.003) |
| ***Medical History*** | | | |
| Total time on TKI (years)  median (IQR)  *Missing* | 7.7  (5.1, 10.7)  *-* | 6.5  (4.8, 10.2)  *1* | 6.9  (4.8, 10.2)  *1* |
| ***Medication*** | | | |
| Imatinib [n (%)] | 43 (88%) | 105 (84%) | 148 (85%) |
| Nilotinib [n (%)] | 2 (4%) | 14 (11%) | 16 (9%) |
| Dasatinib [n (%)] | 4 (8%) | 6 (5%) | 10 (6%) |

Table 2. Effect of various parameters on molecular recurrence.

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **Molecular Recurrence** | | **p-value** |
| **Yes**  **(n = 12)** | **No**  **(n = 162)** |
|  |  |  |  |
| *Molecular cohort* |  |  |  |
| MMR | 9 (75%) | 40 (25%) | 0.0007 |
| MR4 | 3 (25%) | 122 (75%) |
| *Gender* |  |  |  |
| Male | 6 (50%) | 92 (57%) | 0.77 |
| Female | 6 (50%) | 70 (43%) |  |
| *ECOG performance status* |  |  |  |
| 0 | 12 (100%) | 143 (88%) | 0.37 |
| 1+ | 0 (0%) | 19 (12%) |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
| *Age* | 60 (46, 69) | 59 (50, 68) | 0.84 |
|  |  |  |  |
| *Weight (kg)* | 84 (74, 90) | 80 (71, 92) | 0.90 |
|  |  |  |  |
| *Time on TKI (years)* | 7.6 (6.4, 9.1) | 6.8 (4.8, 10.2) | 0.36 |
|  |  |  |  |
| *Time in MMR (years)* | 5.1 (4.4, 6.6) | 5.5 (3.8, 8.4) | 0.68 |
| *Missing* | *-* | *1* |  |
|  |  |  |  |
| *BCR-ABL1 transcript type* |  |  |  |
| e13a2 | 5 (42%) | 29 (22%) | 0.28 |
| e14a2 | 5 (42%) | 72 (55%) |  |
| Other/both | 2 (16%) | 31 (24%) |  |
|  |  |  |  |
| Unknown | - | 30 |  |
|  |  |  |  |
|  | | | |
|  | | | |

Table 3. Serious adverse events during de-escalation.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | Grade | | | | |
| Name (number) of SAE | Treatment cohort | 1 | 2 | 3 | 4 | 5 |
| Myocardial infarction (2),  Syncope (1) | MMR | - | - | - | - | - |
| MR4 | - | 1 (1) | 2 (2) | - | - |
| Abdominal pain (1) | MMR | - | - | - | - | - |
| MR4 | - | - | - | 1 (1) | - |
| Pain in lower limbs\* (1) | MMR | - | - | - | - | - |
| MR4 | - | - | 1 (1) | - | - |
| Gallbladder pain (1) | MMR | - | - | - | - | - |
| MR4 | - | - | 1 (1) | - | - |
| Allergic reaction (1) | MMR | - | - | - | - | - |
| MR4 | - | 1 (1) | - | - | - |
| Sepsis (3),  Urinary tract infection (1),  Skin Infection (1) | MMR | - | - | 1 (1) | - | - |
| MR4 | - | 2 (1) | 2 (2) | - | - |
| Bone pain (1),  Other (1) | MMR | - | - | - | - | - |
| MR4 | - | - | 2 (2) | - | - |
| Urinary retention (1) | MMR | - | - | - | - | - |
| MR4 | - | 1 (1) | - | - | - |
| **Total** | MMR | - | - | 1 (1) | - | - |
| MR4 | - | 5 (4) | 8 (7) | 1 (1) | - |

Table 4. Financial implications of de-escalation.

Patients with molecular recurrence:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| UPN | At trial entry: | | Cohort | TKI cost without de-escalation | Months to recurrence | Total months at half dose | Actual TKI cost (£) | TKI cost saved (£) |
|  | TKI | Dose |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| 8 | Imatinib | 400mg daily | MMR | 23700 | 10.2 | 10.4 | 13596 | 10104 |
| 22 | Imatinib | 300mg daily | MMR | 17775 | 12.0 | 13.8 | 11076 | 6699 |
| 23 | Imatinib | 400mg daily | MMR | 23700 | 8.0 | 8.3 | 15643 | 8058 |
| 44 | Imatinib | 400mg daily | MMR | 23700 | 4.1 | 4.1 | 19736 | 3965 |
| 51 | Imatinib | 400mg daily | MMR | 23700 | 4.8 | 5.3 | 18521 | 5180 |
| 76 | Imatinib | 300mg daily | MMR | 17775 | 4.3 | 4.3 | 15697 | 2078 |
| 79 | Imatinib | 400mg daily | MMR | 23700 | 2.5 | 3.1 | 20663 | 3038 |
| 107 | Imatinib | 400mg daily | MMR | 23700 | 3.2 | 3.2 | 20599 | 3102 |
| 138 | Imatinib | 400mg daily | MMR | 23700 | 5.9 | 5.9 | 17913 | 5788 |
| 28 | Imatinib | 400mg daily | MR4 | 23700 | 8.6 | 8.9 | 15003 | 8697 |
| 89 | Imatinib | 400mg daily | MR4 | 23700 | 8.0 | 8.1 | 15771 | 7930 |
| 99 | Imatinib | 400mg daily | MR4 | 23700 | 12.0 | 12.6 | 11390 | 12311 |

Patients completing 12 months of de-escalation without molecular recurrence:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| No. of patients | At trial entry: | | TKI cost without de-escalation (£) | Total TKI cost saved (£) |
|  | TKI | Dose |  |  |
|  |  |  |  |  |
| 120 | Imatinib | 400mg daily | 2844085 | 1422064 |
| 1 | Imatinib | 350mg daily | 20738 | 8888 |
| 11 | Imatinib | 300mg daily | 195528 | 65176 |
| 1 | Imatinib | 250mg daily | 14813 | 2962 |
| 3 | Imatinib | 200mg daily | 35551 | 0 |
| 10 | Nilotinib | 400mg twice daily | 317356 | 158678 |
| 4 | Nilotinib | 300mg twice daily | 126942 | 63471 |
| 1 | Nilotinib | 225mg twice daily | 23802 | 7934 |
| 1 | Nilotinib | 200mg twice daily | 15868 | 0 |
| 8 | Dasatinib | 100mg daily | 243983 | 121992 |
| 1 | Dasatinib | 80mg daily | 30498 | 15249 |
| 1 | Dasatinib | 50mg daily | 15249 | 0 |

Figure 1. CONSORT diagram of patient disposition during de-escalation.

Screened

N = 335

Excluded, not eligible, declined, other

N = 161

Registered

**N = 174**

MR4 cohort

**N = 125**

MMR cohort

**N = 49**

Relapsed

**N = 9**

Ended study

**N = 1**

Relapsed

**N = 3**

Ended study

**N = 4**

Completed de-escalation phase

**N = 118**

Completed de-escalation phase

**N =39**

Didn’t proceed to stopping phase

**N = 1**

Didn’t proceed to stopping phase

**N = 3**

Proceeded to TKI stopping phase

**N = 117**

Proceeded to TKI stopping phase

**N = 36**

**Figure 2.**

****

A

****

B

Figure 3



REFERENCES

1 Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. *Journal of Clinical Oncology* 2016; **34**: 2851−2857.

2 Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia* 2016; **30**: 1648−1671.

3 Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. *Blood* 2013; **121**: 4439−4442.

4 Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. *Blood* 2016; **128**: 17−23.

5 Saußele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. *Leukemia* 2016; **30**: 1638−1647.

6 Mahon FX, Réa D, Guilhot J, et al; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. *Lancet Oncology* 2010; **11**: 1029−1035.

Updated at: Etienne G, Réa D, Guilhot J, et al. Long-Term follow-up of the French Stop Imatinib study (STIM1) in chronic myeloid leukemia patients. Presented at the American Society of Hematology Annual Meeting, December 2015 [abstract].

7 Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. *Blood* 2013; **122**: 515−522.

8 Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. *Journal of Clinical Oncology* 2014; **32**: 424−430.

9 Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. *Haematologica* 2016; **101**: 717−723.

10 Richter J, Mahon F-X, Guilhot J, et al. Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: Results of the EURO-SKI trial. Data presented at the European Haematology Association 21st Annual Meeting, June 2016, Copenhagen, Denmark [abstract].

11 Kuwabara A, Babb A, Ibrahim A, et al. Poor outcome after reintroduction of imatinib in patients with CML who interrupt therapy on account of pregnancy without having achieved an optimal response. *Blood* 2010; **116**: 1014−1016.

12 Brooks R. EuroQol: the current state of play. *Health Policy* 1996; **37**: 53−72.

13 Bacik J, Mazumdar M, Murphy BA, et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. *Quality of Life Research* 2004; **13**: 137−154.

14 Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. *Blood* 2013; **121**: 5138−5144.

15 Richter J, Söderlund S, Lübking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? *Journal of Clinical Oncology* 2014; **32**: 2821−2823.

16 Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. *Journal of Clinical Oncology* 2003; **21**: 2138−2146.

17 Aziz Z1, Iqbal J, Aaqib M, Akram M, Saeed A. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. *Leukemia & Lymphoma* 2011; **52**: 1017−1023.

18 Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. *Blood* 2013; **122**: 641−647.

19 Efficace F, Baccarani M, Breccia M, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. *Quality of Life Research* 2014; **23**: 825−836.